Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS, Inc. daily Stock Chart
VVUS [NASD]
VIVUS, Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own0.70% Shs Outstand105.57M Perf Week-1.43%
Market Cap145.69M Forward P/E- EPS next Y-0.47 Insider Trans-1.81% Shs Float98.64M Perf Month26.61%
Income-45.40M PEG- EPS next Q0.23 Inst Own35.40% Short Float6.55% Perf Quarter28.97%
Sales57.80M P/S2.52 EPS this Y-12.10% Inst Trans-4.38% Short Ratio13.53 Perf Half Y18.97%
Book/sh-0.36 P/B- EPS next Y-422.20% ROA-16.50% Target Price10.40 Perf Year30.19%
Cash/sh2.69 P/C0.51 EPS next 5Y0.80% ROE193.90% 52W Range0.92 - 1.85 Perf YTD35.29%
Dividend- P/FCF- EPS past 5Y0.80% ROI-26.90% 52W High-25.41% Beta1.40
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin80.90% 52W Low50.82% ATR0.08
Employees82 Current Ratio2.70 Sales Q/Q-46.20% Oper. Margin-22.90% RSI (14)62.15 Volatility5.88% 6.74%
OptionableYes Debt/Eq- EPS Q/Q43.40% Profit Margin-78.60% Rel Volume0.71 Prev Close1.40
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume477.35K Price1.38
Recom2.50 SMA208.32% SMA5018.21% SMA20014.08% Volume337,750 Change-1.43%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Dec-05-16 11:10AM  Increased Earnings Estimates Seen for VIVUS (VVUS): Can It Move Higher?
Dec-01-16 04:20PM  5 Top Performing Biotechnology Stocks of November +5.22%
Nov-21-16 08:25AM  VIVUS (VVUS) Shows Strength: Stock Adds 5.1% in Session
Nov-18-16 01:43PM  ETFs with exposure to VIVUS, Inc. : November 18, 2016 +5.13%
Nov-17-16 01:04PM  VIVUS INC Financials
Nov-14-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Submission of Matters to a Vote of Secur
11:25AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-11-16 02:51PM  VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3
Nov-09-16 09:25PM  Edited Transcript of VVUS earnings conference call or presentation 9-Nov-16 9:30pm GMT
06:25PM  Vivus reports 3Q loss
04:44PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security
04:10PM  VIVUS Reports 2016 Third Quarter Financial Results Marketwired
07:07AM  Q3 2016 VIVUS Inc Earnings Release - After Market Close
Oct-26-16 05:00PM  VIVUS Announces Date of 2016 Third Quarter Business Update and Financial Results Teleconference Marketwired
Oct-12-16 09:20AM  Mylan Up on EpiPen Medicaid Settlement, Cuts 2016 Outlook
Oct-06-16 08:55AM  Earnings Estimates Moving Higher for VIVUS (VVUS): Time to Buy?
Oct-05-16 09:30AM  The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals
Oct-04-16 05:34PM  VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals
01:53PM  Biotech Mergers Run the Show: 5 Small-Cap Stocks for Q4
10:05AM  Roche Alecensa Wins Second Breakthrough Status in the U.S.
Oct-03-16 08:36AM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme
Sep-28-16 04:51PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
05:53AM  Myriad Genetics to Present myRisk Data at Seattle Conference
Sep-27-16 10:24AM  ETFs with exposure to VIVUS, Inc. : September 27, 2016
Sep-09-16 11:33AM  ETFs with exposure to VIVUS, Inc. : September 9, 2016
Sep-06-16 04:09PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreem
Aug-29-16 04:37PM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
04:30PM  VIVUS Extends Return Date of STENDRA Commercial Rights Marketwired
Aug-26-16 10:50AM  ETFs with exposure to VIVUS, Inc. : August 26, 2016
Aug-12-16 02:49PM  ETFs with exposure to VIVUS, Inc. : August 12, 2016
Aug-11-16 10:35AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-09-16 04:08PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Aug-07-16 02:41PM  Edited Transcript of VVUS earnings conference call or presentation 4-Aug-16 8:30pm GMT
Aug-04-16 05:01PM  Vivus reports 2Q loss
04:23PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  VIVUS Reports 2016 Second Quarter Financial Results Marketwired
04:04PM  VIVUS INC Files SEC form 10-Q, Quarterly Report
07:07AM  Q2 2016 VIVUS Inc Earnings Release - After Market Close
Jul-27-16 04:22PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents Marketwired
Jul-26-16 04:15PM  VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference Marketwired
Jul-22-16 06:03AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-21-16 06:01PM  VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation Marketwired
Jun-30-16 04:22PM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
04:15PM  VIVUS to Extend Return Date of STENDRA Commercial Rights Marketwired
12:45PM  ETFs with exposure to VIVUS, Inc. : June 30, 2016
Jun-21-16 04:07PM  VIVUS INC Files SEC form 8-K, Other Events
Jun-17-16 05:37PM  ETFs with exposure to VIVUS, Inc. : June 17, 2016
Jun-09-16 08:58AM  Orexigen Stock Gains More than 50% on Markman Hearing
Jun-03-16 03:48PM  ETFs with exposure to VIVUS, Inc. : June 3, 2016
May-23-16 09:01AM  Im traveling this week, so Im not able to write a new blog post, but I thought I would share the video of the presentation J. Carlo Cannell and I made at last years Stansberry Conference in Las Vegas. Im scheduled to present at the conf
May-18-16 11:01PM  ETFs with exposure to VIVUS, Inc. : May 19, 2016
May-17-16 04:31PM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q1, 2016 By the Numbers
11:31AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS PR Newswire
May-16-16 12:53PM  Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-06-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
May-05-16 04:14PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
May-04-16 10:28AM  Vivus downgraded by WallachBeth -8.67%
08:09AM  VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline
08:07AM  Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
May-03-16 09:34PM  Edited Transcript of VVUS earnings conference call or presentation 3-May-16 8:30pm GMT -5.06%
04:37PM  Vivus reports 1Q loss AP
04:15PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Vivus Reports 2016 First Quarter Financial Results Marketwired
04:05PM  VIVUS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q1 2016 VIVUS Inc Earnings Release - After Market Close CCBN
Apr-19-16 06:00PM  VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference Marketwired
Apr-11-16 11:40AM  VIVUS (VVUS) Upgraded to Hold on Strong Fundamentals
Apr-07-16 09:30AM  Biotech Volatility Both Good And Bad Accesswire
Apr-04-16 03:45PM  ETFs with exposure to VIVUS, Inc. : April 4, 2016 +6.71%
08:05AM  VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Mar-25-16 10:06AM  ETFs with exposure to VIVUS, Inc. : March 25, 2016
Mar-14-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +6.78%
04:07PM  ETFs with exposure to VIVUS, Inc. : March 14, 2016
10:58AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-10-16 09:10AM  VIVUS Posts Narrower Loss in Q4 but Misses on Revenues
Mar-09-16 08:17PM  Edited Transcript of VVUS earnings conference call or presentation 9-Mar-16 9:30pm GMT
04:43PM  Vivus reports 4Q loss
04:23PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:16PM  VIVUS INC Files SEC form 10-K, Annual Report
04:15PM  VIVUS Reports Fourth Quarter and Year-End 2015 Financial Results Marketwired
07:07AM  Q4 2015 VIVUS Inc Earnings Release - After Market Close
Feb-29-16 08:30AM  VIVUS Announces Date of Fourth Quarter 2015 Update and Financial Results Teleconference Marketwired
Jan-28-16 04:47PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-07-16 09:30AM  The Zacks Analyst Blog Highlights: Gilead, MannKind, VIVUS and Baxalta
Jan-06-16 02:50PM  Biotech Stock Roundup: MannKind Tanks on Deal Termination, Speedy Review for Gilead Drug
Jan-04-16 02:40PM  VIVUS to Regain U.S. and Canada Stendra Rights from Endo
Dec-31-15 04:15PM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
01:00PM  VIVUS, Inc. Announces Intent to Reacquire U.S. and Canadian Rights for Stendra(R) (Avanafil) Marketwired
Dec-29-15 09:00AM  A New Take On New Year's And Chronic Weight Management: Smart Changes Program Combines Positive Lifestyle Changes With Prescription Medication For Weight Loss PR Newswire
Dec-23-15 12:43PM  VIVUS, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-04-15 04:57PM  Orexigen Therapeutics, Inc.'s Stock Loses Weight on Downgrade at Motley Fool -7.14%
Dec-02-15 03:20PM  Zafgen Plunges On Death In Obesity-Drug Trial at Investor's Business Daily -6.25%
Nov-30-15 03:00PM  Should You Buy VIVUS, Inc. (VVUS)? at Insider Monkey -9.42%
Nov-29-15 11:17AM  Should You Buy Bravo Brio Restaurant Group, Inc. (BBRG)? at Insider Monkey
Nov-25-15 05:35PM  Drugmakers drop weight
Nov-24-15 04:12PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Nov-23-15 08:20AM  Trading Ahead of Upcoming Developments - Research on Vivus, ReneSola, Consumer Portfolio Services and BioScrip Accesswire +5.69%
Nov-21-15 03:17PM  Do Hedge Funds Love Hurco Companies, Inc. (HURC)? at Insider Monkey
Nov-09-15 04:09PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Varghese Santosh TChief Medical OfficerOct 01Sale1.1471080988,256Oct 04 07:35 PM
Varghese Santosh TChief Medical OfficerAug 02Sale1.0712,55913,43888,966Aug 02 07:07 PM
Varghese Santosh TVP, Medical & Reg AffairsJul 01Sale1.21366443101,525Jul 06 05:12 PM
Varghese Santosh TChief Medical OfficerApr 07Sale1.65329543101,891Apr 11 09:33 PM
NORTH TIDE CAPITAL, LLC10% OwnerApr 01Buy1.402,1603,02813,587,460Apr 05 04:08 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 31Buy1.36172,300234,22513,585,300Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 30Buy1.25100,000125,45013,413,000Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 29Buy1.21111,000133,84313,313,000Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 28Buy1.13177,000199,39013,202,000Mar 28 04:46 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 24Buy1.0925,00027,24213,025,000Mar 28 04:46 PM
Varghese Santosh TChief Medical OfficerJan 13Sale0.951,5531,475102,220Apr 11 09:31 PM